Core Laboratories, Inc.

As of October 24, 2025, Core Laboratories, Inc. shows a mildly bullish trend supported by positive MACD and Bollinger Bands indicators, despite some short-term caution from daily moving averages.

As of October 24, 2025, Core Laboratories, Inc. shows a mildly bullish trend supported by weekly and monthly MACD indicators and Bollinger Bands, despite some short-term caution from daily moving averages.

As of October 24, 2025, Core Laboratories, Inc. shows a mildly bullish technical trend, supported by positive MACD and Bollinger Bands indicators, despite short-term caution from daily moving averages, while significantly outperforming the S&P 500 in the past week and month.

As of October 10, 2025, Core Laboratories, Inc. shows a mildly bearish trend overall, with mixed signals from various indicators across different time frames.

As of October 10, 2025, Core Laboratories, Inc. shows a mildly bearish trend with mixed technical indicators, significantly underperforming the S&P 500 with a year-to-date return of -40.32% compared to the S&P's 11.41%.

As of October 10, 2025, Core Laboratories, Inc. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -40.32% versus the index's 11.41%.

As of August 28, 2025, Core Laboratories, Inc. shows a mildly bearish technical trend with mixed signals across indicators, underperforming the S&P 500 with year-to-date and one-year returns of -26.75% and -30.71%, respectively.

As of July 7, 2025, Core Laboratories, Inc. is considered very expensive with a P/E ratio of 21 and an EV to EBITDA of 10.54, underperforming the S&P 500 significantly with a year-to-date return of -26.75% and a 5-year return of -29.32%.

As of November 1, 2023, Core Laboratories, Inc. is considered very expensive and overvalued, with a P/E ratio of 21 compared to the industry average of 23.39, underperforming peers in key financial metrics and significantly lagging the S&P 500 with a year-to-date return of -32.76%.

As of June 10, 2025, Core Laboratories, Inc. shows a mildly bearish trend overall, with mixed signals from indicators like MACD and Bollinger Bands, suggesting short-term strength but dominated by bearish momentum.

As of March 2022, the management team of Core Laboratories, Inc. includes Lawrence Bruno as Chairman and CEO, with Martha Carnes as Proposed Independent Lead Director, and independent board members Gregory Barnett, Harvey Klingensmith, Michael Straughen, and Monique Van Dijken Eeuwijk.

Core Laboratories, Inc. provides reservoir description, production enhancement, and reservoir management services to the oil and gas industry. As of March 2025, it has a market cap of $595.53 million, with net sales of $124 million and a P/E ratio of 21.00.

As of Jun 18, Core Laboratories, Inc. has a market capitalization of 595.53 million, with net sales of 517.81 million and a net profit of 28.73 million over the latest four quarters. Shareholder's funds are 251.99 million, and total assets amount to 590.41 million.